This guideline is intended for use in UK Genitourinary medicine clinics and sexual health services but is likely to be of relevance in all sexual health settings, including general practice and Contraception and Sexual Health (CASH) services, where men who have sex with men (MSM) seek sexual health care or where addressing the sexual health needs of MSM may have public health benefits. For the purposes of this document, MSM includes all gay, bisexual and all other males who have sex with other males and both cis and trans men. This document does not provide guidance on the treatment of particular conditions where this is covered in other British Association for Sexual Health and HIV (BASHH) Guidelines but outlines best practice in multiple aspects of the sexual health care of MSM. Where prevention of sexually transmitted infections including HIV can be addressed as an integral part of clinical care, this is consistent with the concept of combination prevention and is included. The document is designed primarily to provide guidance on the direct clinical care of MSM but also makes reference to the design and delivery of services with the aim of supporting clinicians and commissioners in providing effective services. Methodology: This document was produced in accordance with the guidance set out in the BASHH CEG's document 'Framework for guideline development and assessment' published in 2010 at http:/www.bashh.org/guidelines and with reference to the Agree II instrument. Following the production of the updated framework in April 2015, the GRADE system for assessing evidence was adopted and the draft recommendations were regraded. Search strategy (see also Appendix 1): Ovid Medline 1946 to December 2014, Medline daily update, Embase 1974 to December 2014, Pubmed NeLH Guidelines Database, Cochrane library from 2000 to December 2014. Search language English only. The search for Section 3 was conducted on PubMed to December 2014. Priority was given to peer-reviewed papers published in scientific journals, although for many issues evidence includes conference abstracts listed on the Embase database. In addition, for 'Identification of problematic recreational drug and alcohol use' section and 'Sexual problems and dysfunctions in MSM' section, searches included PsycINFO. Methods: Article titles and abstracts were reviewed and if relevant the full text article was obtained. Priority was given to randomised controlled trial and systematic review evidence, and recommendations made and graded on the basis of best available evidence. Piloting and feedback: The first draft of the guideline was circulated to the writing group and to a small group of relevant experts, third sector partners and patient representatives who were invited to comment on the whole document and specifically on particular sections. The revised draft was reviewed by the CEG and then reviewed by the BASHH patient/public panel and posted on the BASHH website for public consultation. The final draft was piloted before publication. Guideline update: The guidelines will be reviewed and revised in five years' time, 2022. Design and delivery of sexual health services for men who have sex with men (MSM) Access to sexual health care
Design and delivery of sexual health services for men who have sex with men (MSM)
Access to sexual health care
Addressing the needs of subgroups of MSM. The high and rising incidence of sexually transmitted infection (STIs) 1 and HIV 2 observed in MSM in the UK are a significant public health priority and mean that in any geographical area a range of sexual health services is required. The needs of younger men, men from ethnic minorities, migrants, trans men and men who do not identify as gay or bisexual may not be met through services in Level 3 genitourinary medicine (GUM) clinics alone. Sexual dyad and network determinants and community and structural barriers 3 may mean that some groups of men experience higher rates of HIV despite evidence of lower rates of direct behavioural risk factors. A range of structural and social disadvantages (termed 'syndemics') 3,4 including depression, substance use, violence, sexual stigma and homelessness show a clear doseresponse relationship with risk of unprotected anal intercourse (UAI) and HIV infection in MSM. 5, 6 There is limited evidence that such syndemics are associated with late HIV diagnosis in MSM in the UK. 7 Several of the most effective prevention interventions 8 are deliverable by clinical services and equity of access can be addressed. The interaction between mental health, drug and alcohol use and sexual risk is recognised in the recent Public Health England framework for health and wellbeing of MSM 9 and associated action plan.
10
Younger men across the world are disadvantaged in accessing services 11 and bear a disproportionate burden of STIs and HIV. 12, 13 Younger MSM may prefer to attend generic young people's sexual health services rather than MSM-specific services. 7, 14 Data from Scotland show that men under 25 are more likely to report UAI with two or more partners in the past year than men over 25 and data from Melbourne also suggest that teenage men are less likely to use condoms for receptive anal sex than older men. 15 , 16 Young MSM are more likely to suffer life stressors, anxiety, depression, suicide attempts and post-traumatic stress disorder than their heterosexual peers. 17 A UK cross-sectional study showed a higher HIV prevalence in black and lower prevalence in Asian MSM than in white British MSM 18 and black and minority ethnic (BME) MSM attending a London clinic were more likely to be diagnosed with rectal gonorrhoea than a matched group of white British men. 19 However, a large online survey showed no difference in reported rates of UAI (p=0.8) between any individual ethnic or migrant group. 20 It is not therefore clear whether black or minority ethnicity in the UK confers a greater risk of HIV acquisition in MSM. Phylogenetic analysis suggests that the proportion of HIV infections in UK attributable to transmission between men may be underestimated: 1-11% of samples examined, recorded as heterosexual, were actually from within an MSM cluster. This proportion was higher for Black African men in whom the proportion was 1-21%. 21 
Recommendations
• Addressing the sexual health needs of MSM in any geographical area requires a range of inclusive specialist services. These may include specialist MSMidentified clinics, outreach services and clinics attached to HIV services (1C) • In order to address the needs of younger men, ethnic minority men, men affected by social deprivation and men who do not identify as gay or bisexual; generic sexual health services including Youth Services, Contraception and Sexual Health (CASH) and General Practice services, even if not explicitly identified as services for MSM, must be fully inclusive (1C) • Younger men (under 25 years) are more likely to need intensive risk reduction interventions (1B) • Black African men may be less likely to disclose sex with other men and opportunities for disclosure should be maximised (2C)
Service levels and settings. There are no studies comparing the effectiveness of different service models in detecting STIs in MSM, but there is evidence relating to models of HIV testing. 22 Clinical services that are identified as MSM clinics can significantly increase MSM attendances in established GUM and sexual health services 23, 24 but are the preferred option for only a minority of men. 25 Other services including CASH and GP services may be more acceptable, particularly to younger men and BME men. 26 In a UK survey of HIV-positive men, 9.4% reported using STI services remote from HIV care providers without disclosing HIV status. 27 A majority of MSM surveyed were happy to discuss sexual health with general practitioners but many had not been asked about sexual orientation and were less likely to disclose sexual orientation to a health care worker than family, friends or colleagues. 28 Young USA MSM were significantly (P<0.001) more likely to disclose sexual orientation to a female health care provider than a male one. 29 In the USA non-disclosure of sex with other men is associated with being young, being black and having a low income. 30 Phylogenetic data suggest that this issue may also apply to Black African men in the UK.
21
Many non-GUM sexual health services in the UK do not currently offer the full range of services to meet the needs of MSM 31 and HIV/STI risk assessment and offer of HIV testing were among the poorest areas of performance in a UK national audit of Level 2 and 3 services. 32 
Recommendations
• All sexual health services in a geographical area, including those offered by GPs, CASH and Young Peoples services, should offer a basic level of STI and HIV testing services for MSM (1C) • Specialist MSM clinics can be used to increase MSM attendances in established services (2C) • All health services should establish clients' sexual orientation and partner gender, using established (e.g. census) methodology at registration or during all routine consultations, in order to ensure that health needs are appropriately addressed (2D)
Service design and outreach services. Express-style services are acceptable to MSM 33 and opt-out self-screening has high acceptability in HIV clinics 34 but it is not clear what proportion of MSM attending services are suitable for self-screening services 35 and the approach has been questioned. Anogenital examination in asymptomatic clients including MSM yields few new STI diagnoses in retrospective studies. 36, 37 Many services across the UK offer services including partial or complete STI screens, HIV testing and vaccination for hepatitis A and or B in outreach settings including public sex environments, saunas 38, 39 at one-off events such as Pride events, 40 or at home, 41 with small but potentially important numbers of new infections detected in a variety of settings. There is evidence from the US that providing testing in sex-on-premises venues does not adversely affect client numbers. 42 Offering point-of-care-testing (POCT) for HIV alone results in low levels of referral to mainstream services for other tests and vaccination, 43 suggesting that the aim should be to offer comprehensive screening and vaccination where practicable.
• Routine STI screening need not include examination in asymptomatic MSM (2C) • Outreach services should offer a comprehensive package of STI tests (2B)
History taking
The 2013 British Association for Sexual Health and HIV (BASHH) UK National Guideline on consultations requiring sexual history taking addresses the elements of sexual history taking required in all patients, including MSM. 44 The history should form a comprehensive and holistic risk assessment including factors known to be associated with risk of STI and HIV infection, including frequency and number of condomless anal sex partners, serosorting, seropositioning, negotiated safety and use and understanding of antiretroviral drugs (ARVs) as HIV treatment-as-prevention (TasP) or pre-exposure prophylaxis (PrEP) ('STI and HIV prevention for MSM in the clinic' section). Details of sexual activities conferring risk for enteric infections ('The management of MSM with symptoms of sexually transmissible enteritis and proctitis' section) and hepatitis A including oro-anal sex (rimming) and for hepatitis C (including fisting; 'Hepatitis A, B and C' section) should be included. Discussion of ways of meeting partners including the use of the internet/geospatial social networking applications (apps) ('Pseudoanonymous partners' section), sex-onpremises or cruising venues may be helpful in assessing and addressing risk. Routine assessment of alcohol intake and the use of recreational drugs during sex, including practices such as injecting and bootybumping (taking recreational drugs per rectum) ('Identification of problematic recreational drug and alcohol use' section), problems with sexual dysfunction ('Diagnosis' section) and condom use and errors 45 should be included. History-based screening of exposed anatomical sites is significantly better than symptom-based screening in detecting chlamydial and gonococcal infections in MSM, 46 but there are no studies comparing history-based screening with routine sampling from throat, urethra and rectum in every case. However, the high proportion of symptomless infections and infections in single sites ('Testing for asymptomatic STIs' section) suggests that routine sampling of all sites may be a more appropriate protocol. This can help to avoid a 'tick box' approach to listing anatomical sites of potential exposure disliked by some men 14 and allow history taking to be holistic and focus on other aspects of health and risk behaviour. A comprehensive risk assessment can be used to guide testing, recommended recall periods ('Recall arrangements and frequency of routine STI and HIV testing' section) and the need for behaviour change interventions. In men with rectal symptoms, the presence of tenesmus and constipation is significantly associated with infection with lymphogranuloma venereum (LGV) 47 and further detail may be required in men suspected of having sexually transmitted enteric infections (STEIs). History taking in men with rectal symptoms is covered in 'Diagnosis: History and examination' section.
Recommendations
• History taking should include a holistic risk assessment to identify the factors known to be associated with risk of STI including HIV (see 'Recall arrangements and frequency of routine STI and HIV testing' section) (1C) • Appropriate questioning for hepatitis C risk should be included in the sexual history of all MSM (2C) • In symptomatic men, review should routinely include questions relating to perianal and rectal symptoms (1C) • Questions on drug and alcohol use should be routine in all MSM consultations (1C)
Identification of problematic recreational drug and alcohol use
Alcohol use is more common among adult MSM 48 and in adolescent MSM 49,50 than their heterosexual peers, although data from the third National Survey of Sexual Attitudes and Lifestyles showed higher rates of smoking and recreational drug use but not current binge alcohol use in a population sample of 190 MSM compared to 5069 men who have sex exclusively with women. 51 Attendees at sexual health clinics as a whole have high rates of excessive alcohol use which is associated with STI diagnosis.
52 Self-reported surveys of convenience samples have consistently found that use of recreational drugs in the LGBT population is significantly higher than among women who have sex with women or heterosexual adults. 53, 54 This pattern is also replicated in MSM attending sexual health clinics.
55 A systematic review of 23 studies found only use of methamphetamine and binge alcohol consumption to be significantly associated with increased sexual risk. 56 Evidence in HIV-positive MSM also associates polydrug use, but particularly the use of crystal methamphetamine with high-risk sexual behaviour and incident STI.
57,58 A review of 14 studies on the use of sildenafil found an independent association of sildenafil use in MSM with increased odds of serodiscordant UAI as well as increased risk of STI in MSM living with HIV.
59
Use of inhaled nitrites (poppers) in isolation, without the use of other drugs is common; men may not regard this as recreational drug use and specific questioning may be required.
In recent years it is more common for men to report the use of multiple substances, 58,60 including established 'club drugs' and a range of novel psychoactive substances (NPSs) which continually emerge, 61 and for which the effects and influence on sexual behaviour are less clearly understood. Clinicians' awareness of 'chemsex' (using typically crystal methamphetamine, mephedrone or GHB/GBL specifically to facilitate or enhance sex) among a minority of MSM, particularly in Central and South East London but also in other major cities, has increased dramatically over recent years. Qualitative and observational evidence suggests sex parties involving group sex and use of club drugs has contributed to the high rate of new HIV and hepatitis C infections, including in a subset of chemsex users, transmissions through intravenous use of crystal methamphetamine or mephedrone ('slamming') by inexperienced users or through deliberate sharing of blood injecting equipment. 62 'Club drug' use was associated with higher rates of self-reported UAI in a study of 246 MSM attending clinics in Brighton 63 and selfreport of chemsex on routine enquiry was associated with a significantly higher risk of bacterial STI diagnosis (p<0.001) and with rectal STI diagnosis (p<0.001) in MSM attending two London clinics. 64 Chemsex has also been strongly associated with outbreaks of sexually transmitted Shigella flexneri 3a infection among MSM 65, 66 as well as with cases of rectal LGV infection in HIV-infected MSM. 67 Specialist services report an increase in the proportion of clients seeking help with problems related to crystal methamphetamine, mephedrone or GHB/ GBL. 68 A qualitative study of MSM in Lambeth described MSM involved in chemsex using drugs solely in association with sex, often in clearly defined 'marathon sessions' of up to three days and associated with predetermined decisions to have UAI with men believed to be seroconcordant but also associated with loss of control. 69 High levels of function in other aspects of life such as employment are often maintained and men neither self-identify as drug users nor fit a stereotype of 'drug user'. Routine enquiry regarding recreational drug use is indicated in all men disclosing other risk factors for STI and HIV acquisition and there may be benefit in routinely assessing MSM (e.g. using selfcompleted screening tools) for problematic alcohol and recreational drug use. Brief interventions for problem alcohol use have been found to be effective in a range of primary care settings 70 including nurse-delivered brief interventions in a sexual health clinic 71 and are recommended in NICE guidance. 72 However, a large randomised controlled trial (RCT) in emergency departments showed no effect 73 and a recent RCT of 802 attendees (including 93 MSM) attending sexual health clinics found no significant difference in alcohol intake or condomless sex after six months between a group universally screened for alcohol use and provided with brief advice by a trained clinician and (where indicated) referral to an alcohol health worker compared to a control group. 74 BASHH has provided guidance and recommendations on appropriate screening questions for recreational drug use. 75 Although the harms associated with increased sexual risk in MSM using recreational drugs are of importance to sexual health clinicians, the direct harms of use of 'chemsex' drugs, including the high risk of overdose and low threshold for dependence with GHB/GBL are likely to be an important and immediate risk to health. Sexual health services may offer the sole opportunity for early intervention in MSM prior to presentation to emergency services. The Novel Psychoactive Treatment UK Network (Neptune) has published detailed guidance on the clinical management of acute and chronic harms of club drugs and NPSs, with specific reference to GUM clinics 61 and including detailed guidance on the structure and content of brief interventions in clinical settings. 76 but all sexual health services should be able to meet the needs of MSM. All services offering STI testing should offer testing for MSM including NAAT testing for Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) from throat, urine and rectum, HIV, syphilis, hepatitis B and where indicated hepatitis C serology. National data from the Netherlands suggest that a majority of chlamydial and gonococcal infections in MSM would be missed if extragenital sites are not tested, 77 although there is no published costeffectiveness data to compare this strategy with history-directed testing. Pooling of samples from pharynx, urine and rectum may be a means of reducing costs. 78 It is desirable that hepatitis B vaccination is offered in all settings but the advantages of expanding the availability of HIV and STI testing should not be lost if this is not practicable in outreach situations.
Recommendations

Recommendation
• All services offering STI testing should offer testing for MSM including NAAT testing for NG and CT from throat, urine and rectum, HIV, syphilis, hepatitis B and where indicated (see 'Hepatitis A, B and C' section) hepatitis C serology (1B)
Chlamydia and gonorrhoea. Chlamydia and gonorrhoea are among the most common STIs affecting MSM. Despite only 2.6% of the British male population reporting a same sex partner in last five years, 1 in 2015 MSM accounted for 70% (22,408/32,095) of gonorrhoea diagnoses (a 105% rise over 2012) and 21% (12,805/60,514) of chlamydia diagnoses among male attendees at GUM and integrated GUM/SRH clinic services in England.
1
Infection may be carried at genital and extra-genital sites in asymptomatic MSM. Extra-genital testing of the pharynx and rectum is likely to play an important role in the control of both infections. Prevalence of extra-genital infections is high in UK, European, American and Australasian cohorts of HIV-negative and HIV-positive MSM.
3-25 Whilst the risk of prevalent and incident Chlamydia and gonorrhoea infections is related to traditional markers of increased sexual risk and penetrative anal and oral sex, several non-penile intercourse practices such as rimming, fingering, fisting and sex toy use are also related to extra-genital infection. [79] [80] [81] A substantial proportion of extra-genital infections (70-90% of rectal and 95-100% of pharyngeal) are asymptomatic. 46, 82, 83 Many pharyngeal infections are restricted to the pharynx. 46, 84, 85 Pharyngeal gonorrhoea has a high incidence:prevalence ratio, suggesting spontaneous resolution, 86, 87 in contrast to pharyngeal Chlamydia, where a high prevalence:incidence ratio supports longer-lived infection. Thus, pharyngeal Chlamydia may play an important role in onward transmission. 88 However, a recent longitudinal study did demonstrate spontaneous clearance of pharyngeal Chlamydia in 37% MSM after a median of ten days. 89 Infection of the urethra with Chlamydia and gonorrhoea is also common in MSM, and is associated with a history of penetrative oral and anal sex, but prevalence has been found at similar levels in men reporting only oro-insertive sex. 90 A recent retrospective Australian study suggested oral sex to be significantly associated with urethral gonorrhoea infection (and primary syphilis), but urethral Chlamydia was more strongly associated with anal sex. 91 Both infections may be present in asymptomatic MSM, but in an Australian cohort of 4500 asymptomatic MSM, the prevalence of gonorrhoea in those without urethral symptoms (detected by NAAT) was only 0.04%. 92 Asymptomatic infection of the rectum with gonorrhoea and/or Chlamydia has been identified as a significant risk factor for HIV sero-conversion. This may be as a surrogate marker of sexual risk, or due to changes in local inflammation and immunity, enhancing susceptibility. [93] [94] [95] [96] Infection of the urethra (and possibly rectum) may increase likelihood of HIV transmission in HIV-positive MSM, 97 although interim data from the PARTNER study showed no transmissions from men with undetectable HIV viral loads, despite significant rates of incident bacterial STIs. 98 Higher rates of gonorrhoea and Chlamydia have been reported in HIV-positive MSM than in HIV-negative MSM. [99] [100] [101] [102] Thus, more frequent Chlamydia and gonorrhoea tests should be considered for sexually active HIV-positive MSM.
NAATs have been shown to be significantly more sensitive than culture in the detection of Chlamydia and gonorrhoea, particularly in extra-genital sites. [103] [104] [105] [106] [107] [108] Owing to cross-reactivity with non-gonorrhoea Neisseria species, all NAAT tests for gonorrhoea from all sites should be confirmed with supplementary tests to improve specificity. [109] [110] [111] A positive predictive value (PPV) of at least 90% should be achieved in all cases. 112, 113 Where possible, prior to treatment, all sites positive for gonorrhoea on NAAT should have a culture performed to monitor antimicrobial susceptibility. 112, 114 First-void urine is the specimen of choice for genital sampling for NAAT, but self-taken urethral meatus swabs have recently demonstrated equivalent sensitivity in the detection of both infections, and may be considered. 115, 116 There is evidence to suggest that self-collected pharyngeal and rectal swabs perform as well as clinician-taken swabs from both sites, although published studies are not powered to exclude a difference in performance. Self-taken swabs are highly acceptable to MSM. [117] [118] [119] Cost-effectiveness data are lacking for triple site testing for gonorrhoea and Chlamydia, but one modelling study examining the benefit of rectal screening on reducing HIV incidence alone in San Francisco has suggested that this a cost-saving intervention. LGV. The diagnosis and management of LGV is covered in a recent BASHH guideline. 121 LGV, caused by the L serovars of CT, has been described in association with MSM in the US since the 1970s. 122 Since 2003, LGV infection in MSM has re-emerged with outbreaks in Western Europe (including the UK), North America and Australia. [123] [124] [125] [126] [127] The vast majority of cases identified have presented with a symptomatic procto-colitis, and typical cases have occurred in HIV-positive men practicing higher risk sex. 128, 129 There is a strong association between LGV infection and established or incident HIV infection and with incident hepatitis C infection. 125 Chemsex (specifically the use of GHB), condomless anal sex and fisting are associated with LGV infection. 67, 130, 131 In the UK, the LGV outbreak started in 2003 and the prevalence of asymptomatic infections increased from 6% of serotypes in 2006 to 22% in 2012, 132, 133 meaning that LGV in the UK has now entered an endemic phase. 134 The extent to which LGV is present in asymptomatic MSM, and whether this contributes to sustained cases in the UK, remains unclear. Some early European studies demonstrated a high prevalence of asymptomatic LGV infection in MSM. 135, 136 In contrast, the largest published case finding study in UK MSM to date found LGV positivity to be 0.9% in rectal samples overall, of whom only 5% were asymptomatic, and only 0.04% from the urethra. 137 Early US studies have also failed to detect LGV in asymptomatic cases. 138, 139 However, a more recent case finding study in the UK identified 69 (9%) LGV and 721 (91%) non-LGV CT serovars from 713 men. In those with LGV for whom data were available 15/55 (27%) overall were asymptomatic. 140 These observed differences may be due to methodological differences between studies, due to changes in LGV epidemiology, or secondary to changes in detection with more frequent extra-genital sampling in routine care.
LGV testing should be performed in all MSM with proctitis, regardless of HIV status and in HIVpositive MSM with CT at any site whether symptomatic or asymptomatic. 141 
Recommendation
• Routine LGV typing of symptomatic and asymptomatic Chlamydia infection at any site is recommended in HIV-positive but not in HIV-negative MSM (2C)
Mycoplasma genitalium (MG).
A UK GUM clinic study demonstrated the prevalence of MG infection at the urethra and rectum in MSM to be similar to that of Chlamydia and gonorrhoea (2-6%), and in HIVpositive MSM to be substantially higher (21%).
142
US authors detected 27 (5.4%) positive rectal specimens for MG in 500 MSM, and again there was a strong association with known HIV infection. 143 Other studies have demonstrated much lower prevalence figures (<2%), usually independent of risk factors. 144, 145 Pharyngeal infection has not been described. 145 MG is well described as a cause of non-gonococcal urethritis (NGU). 144 However, MSM with NGU have a lower prevalence of MG than heterosexual men, possibly because of a greater number of possible aetiologies in the former. 146 In the UK MG study, urethral MG infection was strongly associated with dysuria and nearly all men with MG in the urethra were symptomatic. 142 Conversely, rectal infection was largely asymptomatic, a finding reported in other studies, where no association with procto-colitis has been demonstrated. 143, 145 Urethral-to-anal transmission has been described in MSM couples 147, 148 and the asymptomatic nature of rectal infection may provide a reservoir.
A systematic review and meta-analysis has demonstrated an association of MG with HIV infection, although only two of 19 studies included MSM. However, few studies were prospective and thus the nature of the association and the direction of any putative causation remain unclear. 148 It may be that MG infection increases susceptibility to HIV infection, or may be more prevalent as it is a surrogate marker of sexual risk.
Recommendation
• As most urethral MG is symptomatic, and most rectal MG infection asymptomatic and of uncertain consequence, routine testing of asymptomatic MSM for MG infection is currently not recommended in the UK (2C)
Herpes simplex virus (HSV). The seroprevalence of infection with HSV types 1 and 2 is high in HIV-negative MSM and higher still in HIV-positive MSM. 149, 150 A bidirectional transmission synergy exists between HSV-2 and HIV infection. A meta-analysis of 19 prospective studies demonstrated prevalent HSV-2 seropositivity to be a statistically significant risk factor for HIV acquisition among MSM. 151 However, suppression of HSV-2 viral replication with aciclovir in two RCTs has not demonstrated a reduction in the risk of incident HIV acquisition and transmission, possibly because suppression is incomplete with current antivirals. 152, 153 Studies with higher dose antivirals are ongoing. The effect of prevalent HSV-1 infection remains unclear.
Type specific serology can be used to detect prevalent HSV infection in asymptomatic MSM. Western blot testing is not commercially available, but several commercial assays are available which show high sensitivity and specificity in sexually active adults, 154 but PPV can still be diminished when used as a screening tool. 155 Pending further studies and the availability of future prevention strategies such as vaccines, the utility, cost-effectiveness and acceptability of routine screening for asymptomatic HSV infection in MSM attending GUM clinics remain to be determined.
• It is not recommended that routine HSV serology be offered to asymptomatic MSM (2C)
Hepatitis A, B and C. For full details, please see the BASHH National Guideline on the Management of the Viral Hepatitides A, B and C, 2015 156 and the BHIVA Immunisation Guidelines 2015. 157 The rationale for routine testing in asymptomatic MSM is discussed briefly below.
Hepatitis A
Evidence suggests MSM are not at greater risk for hepatitis A infection, and therefore routine screening or testing for susceptibility (with a view to vaccination) is not recommended. 158, 159 However, several outbreaks amongst MSM in metropolitan areas have been recorded, including an outbreak in England and Northern Ireland in 2016-2017. 160 Vaccination should be offered during such times to at-risk MSM attendees including those with multiple partners and those attending public sex venues. 161, 162 Testing for prior exposure before vaccination has been shown to be cost effective. 163 People who inject drugs and those living with HIV, hepatitis B and hepatitis C should be vaccinated in sexual health settings.
Hepatitis B
Incidence of acute hepatitis B in the UK remains low, 164 but MSM represent a risk group and routine testing and vaccination is recommended for those at elevated risk, comprising all MSM, male and female sex workers, and people who inject drugs. 165 Unless already known to be hepatitis B immune or chronically infected, asymptomatic MSM should be tested for previous hepatitis B exposure and vaccination initiated at first presentation. If testing identifies susceptible individuals, the vaccination course should be continued. Chronically-infected individuals should be evaluated and referred to specialist care.
Hepatitis C
Parenteral spread accounts for the majority of prevalent cases of hepatitis C virus (HCV) in the UK. 166 There has been a steadily rising incidence of acute HCV in MSM in England since 2000, largely associated with HIV infection. 166 Associated factors include the presence of other STIs (particularly syphilis and LGV), traumatic anal sex, fisting, shared sex toys, group sex, serosorting and concomitant use of recreational drugs (including injected recreational drugs such as crystal methamphetamine in 'chem-sex' party settings). 167, 168 Whilst permucosal transmission does account for acquisition in HIV-positive men, data are lacking to support significant permucosal transmission in HIVnegative MSM. 169, 170 A prospective US cohort study demonstrated an association of incident HCV with higher numbers of receptive UAI partners, as well as injecting drug use and HIV-positive status. HCV incidence was 0.5 per 1000 PY in HIV-negative MSM compared to 4.2 per 1000 PY in HIV-positive MSM. 171 In a systematic review of 38 cross-sectional studies, the pooled HCV prevalence was found to be significantly higher in HIV-positive men (8.3%, 95% confidence interval [CI]: 6.7-9.9) than in HIV-negative men (1.5%, 95%CI 0.8-2.1). Of the 16 longitudinal studies included, the pooled HCV incidence was markedly higher in clinic-based (7.0 per 1000 person-years, 95%CI 4.6-9.5) than in community-based (1.4 per 1000 person-years, 95%CI 0.7-2.1) studies, and in HIV-positive men (6.4 per 1000 person-years, 95%CI 4.6-8.1) than in HIV-negative men (0.4 per 1000 person-years, 95%CI 0-0.9). 172 Cross-sectional prevalence of HCV amongst non-injecting HIV-negative MSM in the UK is <1.0%. 173 However, MSM eligible for PrEP appear to be a population at significantly increased risk of HCV. A higher baseline prevalence of hepatitis C was observed in men eligible for PrEP at enrolment in the Amsterdam PrEP demonstration project; 18/375 HIV-negative participants (4.8%, 95% CI 2.9%-7.5%) were anti-HCV and/or HCV RNA positive at enrolment; 15/18 (83%) had detectable HCV RNA. All HCV-positive MSM starting PrEP in this study were part of MSM-specific HCV clusters containing MSM with and without HIV. 174 In the UK PROUD study, five of 160 (3.1%) men tested more than once for HCV had incident infection 175 and incident infections have been reported in routine clinical PrEP follow-up. 176 The most cost-effective strategy for HCV testing among asymptomatic HIVpositive MSM is likely to be annual HCV antibody tests and 3-6 monthly testing of liver function. 177 
Recommendations
• Routine HCV testing should be offered to asymptomatic HIV-negative MSM in the presence of additional risk factors (e.g. sex associated with trauma or injury, history of recreational drug use or rectal LGV) (2B) • Hepatitis C testing should be offered at least annually to men eligible for three-monthly HIV testing ('Recall arrangements and frequency of routine STI and HIV testing 'section) and those taking or eligible for PrEP (2B) • HIV-positive MSM should be routinely screened for HCV at least annually, and whenever clinically indicated (1C) 178 but recent localised MSM outbreaks have been described, often linked to the use of geospatial social networking applications. 179 Increased testing in all sexually active MSM may help contain the current epidemic. 180 • All asymptomatic MSM should be tested for syphilis as part of sexual health screening (1B)
Introduction
In 2014, 3360 (55%) of the 6151 new diagnoses of HIV in the UK were made in MSM.
2 Rates of late HIV diagnosis (a CD4 cell count <350 within three months of diagnosis) have declined since 2005 and are lower in MSM than in other transmission groups, although the absolute number of late diagnoses in MSM has declined only slightly from 1131 in 2005 to 974 in 2014. 181 There is a significant geographical variation in rates of late diagnosis, with higher rates outside London. There has been a parallel increase in the proportion of recent infections as defined by the Recent Infection Testing Algorithm. 182 In 2014, 32% of MSM were diagnosed within six months of acquiring infection, compared with 27% in 2012 and 23% in 2011. This finding is consistent with a high incidence of infection and suggests that a high proportion of undiagnosed infections are recently acquired. The proportion of recent infections was highest in the 15-24-year-old age group at 38%, 2 consistent with the age-related vulnerabilities outlined in the 'Addressing the needs of subgroups of MSM' section. 15, 16, 183 Mathematical modelling suggests that the majority of new HIV infections are likely to originate from men unaware of their status and that increased testing, linkage to care and early treatment could contribute to reduced HIV incidence. 184 Hence there is a continued focus on avoiding harm to the individual from late diagnosis of HIV by encouraging and enhancing access to initial tests, but increasing attention to repeat testing to facilitate early diagnosis of recent infection for the purposes of prevention. Revised national BHIVA 185 and international WHO guidance 186 recommends starting ART before the CD4 cell count drops below 500 cells/ mm 3 based on the START study findings, 187 so early diagnosis offers individual clinical benefit but also the possibility of TasP 188 and potentially the use of PrEP for serodiscordant regular partners.
In English GUM clinics in 2014, 87% of eligible MSM attendees were tested.
2 However, seven hundred MSM diagnosed HIV-positive in 2013 were diagnosed on their first HIV test at that clinic 13 and 88% of all individuals diagnosed with HIV at English GUM clinics in 2014 had not had a previous test at the same clinic in the preceding 43-365 days.
2 UK data collected in bars and online in both London and Scotland (n=2409) show that only 26.7% of men reporting higher risk UAI reported having had four or more tests in the previous two years. 189 Public Health England has published a systematic evidence summary on reducing late HIV diagnosis in all patients groups. 190 Improving rates of testing for those with indicator conditions, routine testing in general practice and in acute medical admissions are all likely to improve late diagnosis in MSM in areas with higher overall HIV prevalence. Opt-out testing is the appropriate approach for MSM in all settings 22 and is recommended in existing UK HIV Testing Guidelines 191 and NICE Guidance, 192 both of which are currently being updated. In all cases, identifying MSM in general medical services and general practice is key to routine testing in this group ('Service levels and settings' section) and will be particularly important in areas with lower overall HIV prevalence where universal approaches are not adopted and where existing evidence shows rates of late diagnosis to be higher.
2 A systematic review found RCT evidence that POCT and counselling in community outreach settings (not including general practice) increased uptake of HIV testing in MSM. 22 POCT in community settings identified HIV infection in MSM at a significantly earlier stage than in GUM clinics 193 although whether this is attributable to the test or the setting is not clear. Significant improvements in both the rate and frequency of testing in MSM outside the GUM clinic setting are still required.
Recommendations
• Opt-out testing for HIV infection should be offered to MSM in all settings (1B) • Opportunities for routine HIV testing in MSM in settings other than GUM clinics should be expanded (1C) • POCT for HIV in community settings should be available to MSM (1B)
Motivation for and barriers to HIV testing. NICE Guidance recommends that staff should ensure the provision of culturally competent care in HIV testing and that POCT should be routinely be offered alongside fourth generation laboratory tests. 192 There is some evidence that MSM prefer less intrusive oral HIV testing to blood testing, but if a blood test is used then the waiting time for results is cited by users as being important. 194 A conjoint analysis of factors affecting willingness to test in the US found that cost, timeliness of result and location (home versus clinic) were highly significantly associated with willingness to test. 195 A semi-structured interview study in Boston, US, found that MSM prefer HIV testing in a venue that is friendly, culturally competent, gay-positive and allows for normalisation of STI/HIV testing. 196 A UK study showed the importance of psychological barriers to testing. It showed no reduction in clinic-related barriers to testing over time and highlighted that fear of a positive test result remained the single most important barrier to HIV testing. 197 Attendance for HIV testing is most commonly prompted by symptoms attributed by men to HIV infection and perceived HIV risk exposure. 196, 198 Learning of HIV infection in a partner or friends and peer encouragement to test are also cited as reasons to attend whereas fear of a positive result and not selfassessing as 'at-risk' are given as the main reason for not or never testing. 199 Intensive peer counselling also increased the uptake of testing.
22 Alternative community venues 200 are used for on-site testing including gay saunas, 201 event-related outreach 40 and college-based testing. 202 Offering other tests (e.g. for STIs, alcohol or drug use) along with HIV testing may increase uptake in some groups of MSM. 203 It is estimated that 33-67% of HIV infections in MSM are acquired from primary sexual partners 204 and in the UK approximately 40% of MSM are in a regular relationship at the time of diagnosis.
7 A high proportion of young MSM interviewed in Scotland aspired to sex within relationships 205 and testing within relationships was routine for a minority of men in an online survey of US HIV-negative MSM, in which younger men and those with higher levels of trust in a partner were less likely to test. 206 Couples' counselling and voluntary testing (CVCT) has been utilised in both clinical and non-clinical settings and found to be acceptable and effective on a small scale in the US. An online survey of 5980 MSM found that 81.5% were willing to take part in CVCT. 207 Of 95 couples tested in a study in Atlanta, 17% were serodiscordant. 208 
• Offering HIV tests along with other tests, such as tests for STIs or drugs and alcohol services, may improve uptake among some groups of hard-toreach men (2C) • CVCT for MSM should be provided and promoted (2C)
Home sampling and testing. Home sampling for HIV has high levels of acceptability among UK MSM, with a high proportion of users reporting never having tested before. 41, 209, 210 A possible advantage over home testing is the capacity for laboratory confirmation of an initial reactive result and linkage to care. Home sampling may be promoted and incorporate risk assessment tools via social networking or other websites. 209, 211 Instant result HIV home testing kits were legalised in the UK in April 2014 212 and the first commercially available kit gained a CE licence in April 2015. 213 Mixed methods research on self-testing from the UK showed that amongst MSM (n=999), awareness of the test was low (55%) and that willingness to use was high (89%). 214 In the US licensing studies of one kit (OraQuick/Orasure, Orasure Technologies, Bethlehem, Pennsylvania, US), a lower sensitivity was observed in studies involving unsupervised users than in studies of professionals or supervised users. 215 This suggests that interpretation or possibly acceptance of positive test results may occasionally be an issue. One mathematical modelling study using this sensitivity figure suggested that HIV prevalence in MSM would increase if home testing were to universally replace clinic-based testing. 216 However, as a supplementary strategy home testing addresses some of the recognised barriers to testing 195 and may be utilised by high risk, hard-to-reach groups including MSM who are married to women. 217 The use of voucher systems 218 or incentives 219 for home testing has been explored in the USA but the uptake appears to be relatively low. Guidance for users and service providers has been prepared by a national action group on self-testing for HIV. 220 
• Home sampling should be made available as an option for testing to all MSM (1C) • MSM should be made aware of the availability of instant result home testing as an option for HIV testing (2C) • Clinic services should have pathways in place for quick access and confirmatory testing for those reporting reactive results after home sampling or home testing for HIV (1D)
STI and HIV testing
Recall arrangements and frequency of routine STI and HIV testing. International guidance from the USA, Australia and the UK recommends annual STI testing for all sexually active MSM. 221 US cost-effectiveness analysis suggests that HIV diagnosis is cost-saving up to a threshold cost of $22,909 222 and that testing threemonthly in high risk (annual incidence 1%) and ninemonthly in moderate risk (annual incidence 0.1%) individuals in a test-and-treat model is cost effective. 223 A further modelling study found that increasing testing from annually to three-monthly in MSM is cost saving. 224 An Australian modelling study suggested that increasing HIV testing in MSM from one to four times per year was estimated to have the potential to reduce HIV incidence in NSW by 13.8% over ten years. 225 Cost-effectiveness analysis has been performed for syphilis testing in MSM living with HIV, suggesting three-monthly screening is cost effective, 226 but there is no comparable evidence with respect to other STIs in HIV-negative MSM. A retrospective analysis of the impact of strictly applying (Australian) 221 testing frequency guidelines to MSM attendees at a large UK GUM clinic was estimated to increase MSM testing visits by 30%. 227 There is currently no evidence on which to base a different frequency of routine testing for other STIs than the frequency of HIV testing.
The presence of an acute STI, such as syphilis, Chlamydia and gonorrhoea, is associated with increased HIV acquisition, 228 the strongest association being with rectal infections. 94, 95, 229 HIV incidence varied by the rate of incident syphilis, when controlled for known predictors of HIV in the iPrEx study of HIV PrEP. 230 In a study of 301 MSM diagnosed with a bacterial STI in a London clinic recalled at three months for retesting, of whom 206 attended 231 ; 29 MSM per 100 person-years of follow-up were diagnosed with a new STI and there were five new cases of HIV infection. Given the high rate of HIV transmissions occurring immediately after STI acquisition, and the fact that fourth generation tests for HIV will detect the great majority of HIV infections at four weeks after exposure, 232 a routine test at first follow-up appointment in cases of syphilis, gonorrhoea infection at any site and rectal or urethral chlamydial infection, as well as at three months post diagnosis, will maximise the opportunity for early HIV diagnosis.
Known markers of STI and HIV risk are inconsistently applied across UK clinics, 233 suggesting a lack of consistent evidence and guidance. International guidance on testing frequency from Australia 221, 234 *The definition of long-term exclusive partner used is for more than two years, but there is no evidence on which to derive a threshold for reduced risk.
Recall reminders. SMS text message reminders significantly (p<0.001) increased re-attendance for testing by Australian MSM 238 and increase the detection of gonorrhoea, Chlamydia and latent syphilis. 239 Smaller UK studies suggest SMS text reminders may be more effective in MSM than other risk groups 240 but effectiveness is highly dependent upon physician prompts 241 or preferably automated systems.
Introduction
Rectal symptoms among MSM presenting to GUM clinics are common. 242, 243 Symptoms may be attributable to STIs acquired through anal sex (typically associated with proctitis) and/or those acquired through a faecal-oral route, typically causing gastroenteritis. These infections are referred to in this guideline as STEIs.
Diagnoses of S. flexneri 3a, S. flexneri 2a and Shigella sonnei in men without a travel history have increased markedly 244 while diagnoses in women have remained stable, strongly suggesting sexual transmission between MSM as the cause, and there has been a recent cluster of verotoxin-producing Escherichia coli 0117:H7 (VTEC) found among MSM. 245 It is particularly important to identify enteric pathogens as the cause of symptoms in MSM, as STEIs will often require collaborative work between primary care and GUM/HIV clinicians, microbiologists and local health protection teams to ensure appropriate clinical and public health management is undertaken in a timely manner.
For opportunistic enteric infections in HIV-positive MSM, refer to British HIV Association and British Infection Association guidelines, 2011. 246 
Aetiology
STIs causing proctitis (Table 1) are transmitted rectally through receptive anal intercourse or fomites (fingers, sex toys or other objects carrying these pathogens) or through oro-anal intercourse.
Enteric pathogens, which are statutorily notifiable, tend to cause enterocolitis, although symptoms may overlap with those caused by STIs and there may be dual pathologies. [247] [248] [249] [250] Acquisition of enteric pathogens may be linked to travel or occur in outbreaks related to food in addition to person-to-person transmission (e.g. for norovirus). However, there is increasing evidence that a range of enteric infections may be transmitted during sex between men (Table 1) . Faecooral transmission may be through direct oro-anal practices, indirectly through oral sex after anal sex or via fingers (either directly into mouth or via food) or fomites.
Infectious causes of gastrointestinal infections in MSM include [252] [253] [254] :
• Viruses: Hepatitis A (see 'Hepatitis A, B and C' section), norovirus (in immunocompetent patients, adenovirus and rotavirus are implicated in childhood gastroenteritis only) • Bacteria: Campylobacter spp., E. coli, Salmonella spp., Shigella spp., Yersinia enterocolitica (N.B. gastrointestinal infections not associated with transmission via sexual practices in the UK: Vibrio cholerae, Clostridium difficile, Bacillus cereus) • Parasites: Cryptosporidium spp., Entamoeba histolytica, Giardia lamblia/intestinalis, Blastocystis spp., Dientamoeba fragilis, Isospora spp., Microsporidium spp.
A national outbreak of S. flexneri 3a in MSM started in 2009, and there is good evidence of sustained transmission of S. flexneri 2a and S. sonnei between MSM since 2010, suggesting separate introductions in the MSM population. 244 Most MSM with S. flexneri 3a were white, UK born, HIV-positive and reported high numbers of casual and regular partners, and infection was associated with (i) low awareness about enteric infections, (ii) chemsex and (iii) meeting sex partners and locating sex parties through social and sexual networking applications. 66, [244] [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] [255] [256] Co-infections with other STIs and with viral hepatitides and HIV are also common. 66, 248, 250, 255, 257, 258 Reduced sensitivity to antimicrobial agents, particularly to fluoroquinolones and macrolides [259] [260] [261] [262] is a significant problem for some enteric pathogens and for STIs such as NG [263] [264] [265] and MG. 145, 266, 267 Appropriate selection of antibiotics (antibiotic stewardship) is therefore required, based wherever possible on antibiotic susceptibility profiles.
Clinical features
MSM reporting symptoms of enteric or rectal infections usually fit into one of two presentation types, although mixed symptoms are not uncommon (Figure 1) . 247, 248, 250, [268] [269] [270] Symptoms of proctitis include rectal pain, discharge or bleeding, with or without tenesmus. The aetiology is usually classic STI pathogens (CT including LGV serovars, NG, T. pallidum and HSV) transmitted via receptive anal sex. 247, 249, 250, 268, 271 Treatment of these pathogens is covered in the appropriate BASHH guideline. MG, though found in the rectum, is not thought to be associated with a proctitis syndrome. 142, 143, 145, 272 Patients with symptoms of enteric infections including diarrhoea and/or dysentery and abdominal pain usually have colitis or enterocolitis that is caused by enteric pathogens, referred to in this guideline as STEIs. Mixed proctitis/STEI presentations and multiple infections are not uncommon.
Management
Proctitis. Symptoms of rectal pain, bleeding with fresh blood and discharge are indicative of involvement of the rectum and the anal canal. See Figure 2 for assessment.
Diagnosis: History and examination. The history should include a description of symptoms and duration. 44, 273, 274 The sexual history should focus on the four-week period prior to onset of symptoms (to cover the look-back period for LGV and gonorrhoea). 275 A thorough genito-anal examination is required 128, 271 including examination with a proctoscope if tolerated. 276, 277 In cases of severe proctitis, blind (i.e. without the use of the proctoscope to visualise the mucosa) anorectal swabs may be necessary.
Diagnosis: Investigations.
A full sexual health screen should be offered 271, 278, 279 ('The range of tests provided' section). Microscopy of a Gram-stained rectal smear should be performed and where possible culture for NG from all sites prior to treatment if it is to be given. Additional swabs for HSV PCR and T. pallidum PCR (where available) should be taken if ulcers are present.
A finding of >5 280 or >10 136 polymorphonuclear cells/high power field on microscopic examination of a Gram-stained rectal swab smear indicates proctitis.
Recommendations
• A full sexual health screen should be offered (1B)
• Rectal swabs should be sent for culture and sensitivities for NG if treatment is to be given at presentation (1B)
Further investigations and treatment. Management is summarised in Figure 3 . CT or LGV as an aetiology must be considered in addition to other diagnoses indicated by examination findings (such as HSV or syphilis with ulcerative features). 271 Examination and findings of microscopic examination of Gram-stained smears from rectal swabs should guide therapeutic decisions and follow the relevant specific infection guideline (accessed at: https://www. bashh.org/guidelines).
If CT is detected, testing for LGV-specific DNA should be done by sending the residual NAAT specimen or a fresh rectal swab to the local microbiology laboratory
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Empirical treatment should cover LGV 121, 271 and gonorrhoea as the prevalence of NG amongst MSM is high and the sensitivity of microscopic examination of Gramstained rectal swabs for gonorrhoea is low. 281 Patients with rectal STIs are at high risk for other STIs, including HIV and hepatitis C and so follow-up STI and HIV testing both at test of cure and at three months is recommended. 282 
Recommendations
• Rectal Chlamydia, if detected, should be typed for
LGV serovars in HIV-positive and HIV-negative MSM with proctitis (1B) • Examination and findings of microscopic examination of Gram-stained smears from rectal swabs should guide therapeutic decisions (1B) • Empirical therapy, in symptomatic men with proctitis in whom the rectal chlamydial status is unknown, should include LGV (which also effectively treats syphilitic proctitis) and gonorrhoea treatment (1B) • Offer hepatitis C testing to all HIV-positive MSM and HIV-negative MSM with risk factors at three months' follow-up (1D)
Contact tracing and treatment. Partner notification (PN) for STIs is covered in the BASHH statement on PN. 275 
Recommendation
• Active PN covering up to at least the four-week period prior to symptom onset should be attempted and documented (1B)
STEIs. Enteric infections are characterised by sudden onset of diarrhoea, with or without vomiting and are usually transient disorders due to enteric infection with viruses, bacteria or protozoa, typically affecting the large bowel (the colon) and less commonly, the small bowel. Other symptoms include blood and/or mucous in the faeces (dysentery), and fever or malaise.
The diagnosis is usually made on the basis of clinical symptoms and signs. Microbiological tests of faecal samples are necessary to determine the causative organism. Infectious bloody diarrhoea as a clinical syndrome is a notifiable infection and should be notified to the Local Authority Proper Officer ('Advice on preventing the non-sexual spread of infection' section).
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Diagnosis: History and examination. Assessment is summarised in Figure 4 . 65, 66, 253, 254, 285, 286 History should include questions on the severity of illness, medication and risk factors, including travel abroad and food history ( Figure 5 , Appendix 2). Sexual risks within the two weeks preceding onset of symptoms should be assessed including receptive oro-anal sexual contact (both direct as well as indirect, i.e. performing oral sex after anal penetration (of another partner)), multiple sexual partners and participating in group sex, sexual activity involving recreational drug use (chemsex -'Identification of problematic recreational drug and alcohol use' section) and sexual activities involving faeces (e.g. scat play).
Symptoms of diarrhoea may be mild and may not be elicited in the history without direct questioning if other symptoms of discomfort, pain or tenesmus predominate.
Symptoms of STEI tend to be acute. However, with parasitic infections such as giardiasis and amoebiasis, chronic symptoms are not uncommon.
LGV may also present as a chronic enteritis with a presentation not unlike inflammatory bowel disease.
Examination should include assessment of the severity of infection, including the severity of dehydration (Appendix 2), particularly in patients who are unwell or frail (older age, advanced HIV infection or other comorbidities). The presence of blood/mucous in faeces, prolonged (more than seven days) diarrhoea and systemic features, such as fever (especially), weight loss and dehydration, would be considered indicative of severe infection and hospital admission should be considered.
Examination of the patient should include assessment for proctitis as described above ('Diagnosis: History and examination' section).
Recommendation
• History should cover assessment of duration and severity of symptoms, identify potential causes and risk factors for complications and public health risk (1B)
Diagnosis: Investigations. Investigations should include a full sexual health screen as described in 'Diagnosis: Investigations' section.
Microbiology examination of stool is recommended in all cases and is essential when the patient:
• needs antibiotics.
• is systemically unwell.
• needs hospital admission.
• has blood, mucous or pus in stool.
• has diarrhoea after foreign travel.
• is immunosuppressed.
Include examination for ova, cysts and parasites (up to three samples taken at three different occasions might be needed), culture with antibiotic susceptibility testing, and where available, molecular detection assays (such as PCR). It is important that the faecal samples are collected properly (as described in 'Guidance on collecting a faecal specimen for microbiological examination' section of Appendix 2) and for each investigation, a minimum of 1 ml of faeces is required.
Recommendations
• Assess for severity including evidence of dehydration (1A) and fever • Consider referral to tertiary care or specialist inpatient units for severe infections (1A)
Further investigations and treatment. The majority of patients with STEI have a brief self-limiting illness and can be managed conservatively. 253, [287] [288] [289] [290] Oral rehydration therapy, if required, consists of using oral rehydration salts taken after every loose stool passed for up to 48 h. 253, 289 Antidiarrhoeal (or antimotility) drugs such as loperamide are contraindicated for the management of infectious diarrhoea. 253, 289, 290 The use of empirical antibiotic therapy, where the diarrhoea is mild and of unknown aetiology, is not recommended. Evidence suggests that they have minimal benefits, with high rates of side effects reported 253, 288, 291 and their use promotes the development of resistant bacteria. 260, [291] [292] [293] Circulating Shigella spp. and other enteric infections are reported to have high prevalence of resistance to antibiotics, particularly macrolides and fluoroquinolones. [259] [260] [261] [262] 292, 294, 295 However, empirical therapy guided by microbiology advice based upon most likely aetiology may be considered when:
• The patient is pyrexial (temperature !38 C) • The stools are bloody • Diarrhoea lasts more than seven days • Co-morbidities (frailty, inflammatory bowel disease, immunocompromised state, e.g. advanced HIV infection, immunosuppressive agents, etc.) are present
Where a microbiological cause is known antibiotic therapy may be appropriate. The choice of agent is best guided by microbiology advice informed by either antibiotic susceptibility profile of an isolate or from local susceptibility data.
HIV-positive patients were reported to have more recurrent, persistent and invasive infections in the pre-HAART era. There are a few case reports of invasive shigellosis in MSM with well-controlled HIV infection. However, there are no data comparing clinical outcomes of STEI in well-controlled HIV-positive MSM and MSM without HIV.
• Advise on oral rehydration therapy (1A)
• Avoid antimotility agents if invasive disease or infectious agents are suspected (1A) • Consider empirical antibiotic therapy only in severe disease or in the presence of complicating comorbidities (1A) • Antibiotic therapy should be guided by local antimicrobial resistance patterns (1B)
Preventing the spread of infection
All patients with suspected or confirmed STEI should be provided with advice on the prevention of nonsexual and sexual transmission of infection. Clinical syndromes of infectious bloody diarrhoea, haemolytic uraemic syndrome and food poisoning, even of unproven aetiology, are statutorily notifiable ('Other public health actions' section).
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Advice on preventing the non-sexual spread of infection 285 . Detailed advice should be provided on the non-sexual transmission of infection ('Advice on preventing spread of infection 285 ' section of Appendix 2).
Recommendations
• Advise on hygiene (1B)
• Advise to avoid return to work until 48 h after last episode of diarrhoea (1B) • For patients who work as food handlers or with people vulnerable to infections, return to work should be guided by local public health authorities (statutory requirement, 'Other public health actions' section)
Advice on sexual practices for preventing spread of infection 296 .
• Wash hands, genitals and perianal skin before and after sexual activities such as intercourse, rimming, fingering or handling used condoms and sex toys. If possible, showering is advised as bacteria like Shigella may be present on other skin surfaces.
• Use condoms for anal sex and latex gloves for digital penetration or fisting. Dental dams or a condom cut into a square to make a barrier for rimming.
• Avoid sharing sex toys or douching equipment.
• Avoid recommencing sexual contact until seven days after the last episode of diarrhoea.
• Advise on hygiene practices before and after sexual contact (1B) • Advise on barrier protection and refraining from sharing toys or personal hygiene devices (1B)
• Advise on abstinence from sexual contact for seven days after the last episode of diarrhoea (2D)
Other public health actions. Effective management of enteric pathogens requires notification to the Local Authority proper officers under the respective Health Protection (Notification) Regulations and Public Health Acts in each country. 283 Lists of notifiable diseases and organisms and associated guidance on how to report in each country are available (see Health Protection (Notification) Regulations and Public Health Acts in each country). Clinical syndromes should be reported by the attending clinician who first saw the patient for the episode; laboratory diagnoses are, in addition, statutorily reported separately by laboratory personnel.
Local health protection teams and environmental health officers will often need to contact patients to undertake a questionnaire to ascertain the likely source of infection and linked cases. For patients diagnosed with STEI it may be appropriate for the GUM clinic to assist in completing the questionnaire and obtaining this information, and collaborate closely with the local health protection teams. 284 
Recommendation
• The attending physician should report all cases, with contact details, of enteric infections, regardless of confirmation, to the relevant local health protection team (statutory requirement) 
Asymptomatic infections
The majority (>80%) of rectal STIs are asymptomatic 297 and are a reservoir for onward transmission and increase the risk of HIV acquisition and transmission. 298, 299 Treatment results in a reduction in onward transmission of the infection 300 as well as of HIV. 298 However, there are no data on asymptomatic carriage of enteric pathogens within cohorts of MSM.
Testing and treating asymptomatic contacts of STEIs for enteric infections is not recommended at present. MSM with enteric infections, however, are part of a sexual network that is high risk for other STIs; engaging contacts of STEI with STI testing and prevention interventions is good clinical practice from a public health STI control perspective.
HPV infection and anal dysplasia in MSM
HPV infection
Two issues arise with HPV infection in the anogenital area in MSM; genital warts and epithelial neoplasia. HPV subtypes 6 and 11 cause genital warts; subtypes 16, 18, 31 and 33 are associated with neoplasia. HPV may also infect and persist in the oropharynx and may lead to oropharyngeal squamous cell carcinoma. Anogenital warts in MSM should be managed according to current BASHH guidelines. 301 Anal dysplasia. Screening for anal dysplasia in MSM using anal cytology remains controversial. Although biennial screening for AIN in HIV-negative MSM has been suggested 302 it is not routinely practiced and cost-effectiveness is unproven. MSM with HIV are reported to have a higher frequency of prevalent high-risk HPV strains, persistence of HPV, incident anal dysplasia, progression to and relapse of anal intra-epithelial neoplasia (AIN) and anal cancer than heterosexual men and women. 303, 304 An Australian meta-analysis estimated an anal cancer rate of 46 per 100,000 HIV-infected MSM, with US rates around 135 per 100,000. 305 An evidence-based UK costeffectiveness analysis in 2010 concluded that screening did not reach the cost-effectiveness threshold, 306 although an Australian study published in 2000 showed that two-or three-yearly screening in MSM was cost effective. 307 Smoking is identified as a risk factor for external genital warts, anal dysplasia and anal cancer among HPV-infected MSM. 308, 309 Lower CD4 cell counts (<350 cells/ml) are strongly associated with prevalent high-risk HPV strains (OR 3.65; 95% CI, 1.28-10.4). 309 There are no RCTs evaluating impact of antiretroviral therapy (ART) on HPV or dysplasia. Some cohorts report lower prevalence of HPV and anal dysplasia, 310 others report no effect with ART. 311 Despite the high rates of abnormalities reported there are no evidence-based recommendations on screening for anal dysplasia. Where expertise in high resolution anoscopy exists, routine anal cytology may be performed, 312 although the specificity of the technique in detecting high-grade lesions is only 32-59%, 313 meaning that a screening programme is likely to be highly resource intensive.
Retrospective studies of large-scale screening programmes suggest that the vast majority of anal cancers present with a lump and over half of anal cancers detected by digital examination are asymptomatic. There is limited evidence that a screening programme utilising perianal examination and digital ano-rectal examination (DARE) is both acceptable and depending on the base case variables used might be cost effective for HIV-positive MSM. 314 Screening those over 50 every two years yielded an incremental costeffectiveness ratio per quality-adjusted life year of AUD 29,760 compared with AUD 45,484 for screening four-yearly.
However, questions remain. Only one small, shortterm study on acceptability has been published. 315 In this study 28% of those approached declined to take part. The cost-effectiveness models above were partly based on this study. These models were very sensitive to the costs of managing false-positive results and to assumptions regarding sensitivity of screening and rates of progression. While non-Australian health care costs were modelled these findings were not published. The European AIDS Clinical Society Guidelines recommend that digital anal examination AE PAP smear every 1-3 years in MSM with HIV infection should be considered but this is an expert recommendation only. 316 To date the recommendation has not been taken up by other guidelines. The possibility of using digital anal self-examination has been explored but there is insufficient evidence on which to base any recommendation. 317 HPV may also affect the oropharynx where it may lead to squamous cell carcinoma. Ong et al. 318 found 19% (33/173) of MSM with HIV had any oral HPV genotype detected, 43% of these had the same genotype detected three years later and 40% were high-risk genotypes. This compares with a prevalence of 7% for any oral HPV in general population. 319 HPV persisted in HIV-negative MSM for a median of 6.9 months for any HPV genotype and 6.3 months for high-risk strains. 320 However, there are no data to suggest an increased frequency of oropharyngeal cancers in MSM and some to suggest that, in HIV-infected MSM at least, the frequency may be lower than in heterosexual men when matched for partner numbers and other risk factors. 321 Oral HPV testing remains a research tool and is not currently recommended in clinical practice.
Recommendations
• Genital warts in MSM should be managed according to existing BASHH guidelines (1C) • HIV units should develop either local clinical expertise or referral pathways for suspected anal cancer and anal dysplasia (2C) • Regular DARE can be incorporated into routine HIV care and may be cost effective in MSM aged over 50 years (2B)
HPV vaccination in MSM
HPV vaccine is most effective when administered before the onset of sexual activity. However, in the UK, universal HPV vaccination is only available for girls. Unvaccinated heterosexual boys benefit from herd immunity but young MSM do not experience significant benefit. 322 In November 2014, the (UK) Joint Committee on Vaccination and Immunisation (JCVI) issued an interim position statement, having reviewed an unpublished impact and cost-effectiveness analysis on vaccinating MSM when attending sexual health clinics. JCVI recommended that a programme for the vaccination of MSM aged 45 years and younger should be implemented in GUM and HIV clinics in the UK using the quadrivalent HPV (qHPV) vaccine with a three-dose series (0, 1-3 and six months or 0, six and 12 months), subject to the programme being commissioned and implemented at a cost-effective price. 323 Vaccination is available at a number of pilot sites in England and at clinics in Scotland. Dosage timings can be adjusted to correspond with routine sexual health or HIV clinic visits. For guidance, in a three-dose schedule, the second dose should be administered at least one month after the first dose and the third dose should be administered at least three months after the second dose. All three doses should ideally be given within one year; however, a 24-month period is clinically acceptable.
Acquisition of HPV. The prevalence of high-risk HPV increases quickly in MSM throughout the late teens and is strongly associated with numbers of sexual partners. In a group of 16-20-year-old MSM in Australia the proportion of men with anal HPV of any type increased from 10.0% in men reporting no prior receptive anal sex to 47.3% in men reporting !4 receptive anal sex partners (P < .001). A similar pattern was also seen with HPV type 16 (P ¼ .044). However, there is also evidence that a substantial proportion of MSM appear to remain uninfected with vaccine specific/targeted types into their 20s and 30s. In a London study 25.1% of MSM aged between 18 and 40 had DNA evidence of one quadrivalent vaccine HPV type, while only 7.4% had presence of two HPV vaccine types or more. These findings offer the possibility that HPV vaccination may also benefit older individuals. 324 qHPV vaccine efficacy in MSM -HIV-negative. The efficacy of qHPV vaccine was investigated in a placebocontrolled trial of 4065 HIV-negative males including 602 MSM aged 16-26 years followed for a median of 2.9 years. 325 Vaccination resulted in a 63.7% reduction in external genital lesions related to vaccine HPV types in heterosexual men and 70.2% (23.0-90.2) in MSM (intention to treat [ITT] ). The per protocol efficacy was 90.5%.
The efficacy of qHPV vaccine in 16-26-year-old MSM against AIN was 50.3% (ITT) and 77.5% (per protocol). 326 Incident AIN was 17.5 per 100 personyears in the placebo group. qHPV vaccine is highly immunogenic in MSM. 327 For those participants without serological or PCR evidence of infection with relevant HPV types at baseline, seroconversion rates at seven months were 96.5% for HPV-6, 97.4% for HPV-11, 94.1% for HPV-16 and 89.7% for HPV-18.
qHPV vaccine efficacy -HIV-positive. There is a comprehensive review of HPV vaccination in the recently published BHIVA vaccination guidelines.
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HPV vaccination is considered safe and seroconversion rates are usually greater than 85%. In some but not all studies, seroconversion rates and antibody titres are highest in those receiving ART and those with higher CD4 cell counts. There is very limited cohort evidence that vaccinating individuals with high-grade anogenital dysplasia reduces the risk of recurrent dysplasia 328 and that such a strategy would be cost effective or even cost saving. 329 RCTs are needed.
Nonovalent (9-valent) HPV vaccine. The US Advisory Committee on Vaccination Practices recommended the use of 9-valent HPV vaccine for routine vaccination including MSM up to the age of 26 years in March 2015. 330 US providers will move from the use of quadrivalent to 9-valent vaccine over the course of 2016. Discussion of 9-valent vaccine is not included in the recent JCVI interim statement on vaccination of MSM in the UK. 323 Economic analysis. In a cost-effectiveness modelling analysis of targeted HPV vaccination of young MSM in the USA, vaccination was considered likely to be cost effective even when considering vaccination of 26-year-olds with an assumption of exposure to vaccine HPV types of 50%. 331 In an unpublished UK analysis reviewed by the JCVI, vaccinating HIV-positive MSM was incrementally cost effective up to age 40 using the list price of qHPV. Vaccination of all MSM was cost effective at a threshold vaccine price (not stated) below list price but was not cost effective at list price. 157 HPV vaccination to reduce risks of HIV transmission. In a meta-analysis of observational studies, prevalent HPV was associated with an approximate doubling of risk of HIV acquisition. 332 However, in the one study within this report performed in MSM, infection with one HPV type compared with no HPV infection was not significantly associated with HIV acquisition (aHR=2.0 [95%CI=0.61-6.5]). However, the presence of infection with two or more HPV types compared with being HPV uninfected was associated with HIV acquisition (aHR=3.5 [95%CI=1.2-10.6]). 333 HPV vaccine acceptability. In a systematic review of HPV vaccine perceptions amongst MSM, a wide range of views were reported. However, more than 50% of individuals were prepared to consider vaccination if offered. Most studies were conducted in North America. Further studies in those with little or no sexual experience, who would benefit most from HPV vaccination, are required. 334 
Recommendations
• MSM should be encouraged to attend sexual health services for preventative health interventions including hepatitis B and HPV vaccination at the time of considering commencement of sexual activity (1B) or as early as possible after commencing sexual activity (1B) • All MSM aged 45 years and younger should be offered standard HPV vaccination (0, two and six months) irrespective of HPV and HIV status (1B)
Partner notification and MSM
Introduction
Partner notification (PN) in MSM should follow general guidance provided by the Society of Sexual Health Advisers 335 and by BASHH in 2012. 275 A systematic review of PN strategies and outcomes concluded that in MSM PN can reduce disease incidence, condomless sex, sex with infected partners, reinfection rates and other adverse outcomes. 336, 337 Recognised barriers to PN such as resistance affect MSM, 338 but other factors including higher partner numbers and sex with anonymous and pseudoanonymous partners may present additional challenges. Attitudes to PN vary significantly according to partner status and the infection involved. 339 
Anonymous partners
PN which relies on a case-finding approach alone has always had limited effect in MSM in whom sexual contacts may be anonymous, contacted through established methods of meeting partners including sex-on-premises venues such as saunas or in public sex environments. Where no contact details are available, 'hot spotting' is a technique for identifying where the index client met their contacts. Real or virtual venues or sites that are recurrently named as meeting places are targeted with health promotion information with the aim of facilitating testing. Although it may not be possible to identify a core group or individual in person it may be possible to reduce the ongoing transmission of infections through the identification of common venues. 340 The delivery of such information may include online and appbased interventions. 
Pseudoanonymous partners
Use of the internet to find sexual partners is extensive and more commonly reported by MSM than other STI clinic attendees. 342 Men who use the internet to meet partners have a greater number of partners 343 and a higher probability of being diagnosed with an STI 344, 345 than men recruited in community-based or national probability samples. Meta-analysis showed that UAI, including UAI with serodiscordant partners, was more common in men who met partners online. 346 Social media sites and more recently Geosocial networking smartphone apps (apps) are widely used in combination with pseudonyms, which preclude the use of names, addresses or telephone numbers in tracing contacts. A systematic review of new technology in PN identified 379 papers published 2000 to 2012. 347 MSM were the first patient group in whom provider use of the internet for PN was reported and much of the published literature applies to MSM. Only one published study compared provider PN using the internet to 'conventional PN' in an unmatched patient group, finding it to be less effective when used instead of conventional methods. 348 However, as an adjunct to conventional methods it increased the number of syphilis contacts tested and treated by 26%. 349 Several studies show it to be more acceptable to MSM than to the general population 350 and a high proportion of English MSM reported that they would engage with a health care worker in an online chat room. 351 Patient-initiated PN is supported by the LetThemKnow tool used in Melbourne 352 and a digital contact slip piloted in the UK by SXT Health Community Interest Company (CIC). 353, 354 Smartphone apps have overtaken the internet as the most common method for meeting partners for casual sex, 355 but there are as yet no systems that allow direct linkage to these apps in order to send messages directly to contacts who need to be notified. The engagement of app providers with health care organisations is variable and some apps exist with the explicit purpose of facilitating condomless anal sex. A large cross-sectional study in Los Angeles found that men who used apps to meet partners had a higher probability of being diagnosed with Chlamydia and gonorrhoea (but not syphilis or HIV) than men who met using other methods. 356 There is evidence that men who use apps have a higher number of partners (both on and offline) than men who meet partners offline alone, but do not differ in other demographics or personality variables. 357 The app profile information often includes no true identity details, so patient referral is the only mode of PN currently possible in situations where an app contact has not been followed up by SMS text or internet contact. Patient-initiated PN using email appears to be more acceptable to MSM than to other patient groups but where options are available communication in person is preferred to the use of email or e-card, or to text messaging. 358 Patient-led referral is preferred for regular and known partners whereas provider-led referral is preferred for casual partners. 
STI and HIV prevention for MSM in the clinic
Introduction
Combination HIV prevention requires a multifaceted approach encompassing behavioural, biomedical, structural and increased testing interventions, including those delivered in clinical settings. 359 Brief behaviour change interventions for MSM, including consideration of serosorting and negotiated safety for HIV-positive MSM are covered in the UK National Guideline on Safer Sex Advice. 45 
Antiretroviral PrEP
PrEP effectiveness. An overall reduction in HIV transmissions of 44% (95%CI 15-63%) was reported in the iPrEx study, the first large randomised placebocontrolled efficacy trial of daily oral tenofovir disoproxil fumarate (TDF)-emtricitabine (FTC) as PrEP in MSM and transgender women. 360 TDF alone has been demonstrated to be effective in heterosexual men and women but is not recommended in MSM in CDC or European PrEP guidelines (due to lack of evidence of effectiveness rather than evidence of no effect). 235 The PROUD study, a pilot study of the use of daily oral PrEP (TDF-FTC), conducted in MSM attending 13 sexual health clinics in England was subject to early discontinuation of the deferred treatment arm due to an unexpectedly high rate of HIV in this group (nine per 100 person-years) and an 86% (90%CI 64-96%) reduction in HIV seroconversions in men in the immediate treatment arm. 361, 362 PROUD inclusion criteria were the reporting of condomless anal sex on one or more occasions in the last 90 days and the likelihood in the opinion of the participant of further condomless anal sex in the next 90 days. The ANRS IPERGAY study of 'on demand' use of TDF-FTC PrEP (two tablets 2-24 h before sex and one tablet a day through to two days after the last condomless sex act) also showed an 86% reduction in HIV seroconversions compared to placebo. 363 Adherence to on demand PrEP (defined as reporting taking at least one tablet before and one tablet after sex) was 43%; no tablets before or after were taken in 28% of sex acts, and suboptimal adherence (one before or one after) was reported in 29% of acts. In spite of this, effectiveness was very high, suggesting that participants were able to judge the risk with reasonable accuracy. The median monthly dose of tablets of 15 was approximately half of the total monthly dose of tablets in the PROUD study. Such a regimen offers obvious potential financial and cost-benefit implications. Importantly it offers a choice of regimen for MSM whose frequency of risk is diverse.
The CDC has provided comprehensive guidance on PrEP use. 235 A joint BHIVA BASHH position statement on PrEP in UK was updated in May 2016 and includes guidance for clinicians providing advice on and monitoring for PrEP including that purchased online. 364 A BASHH/BHIVA UK Guideline on PrEP is in preparation.
Recommendations
• PrEP with on demand or daily oral tenofoviremtricitabine (TD-FTC) should be offered to HIVnegative MSM who are identified as being at elevated risk of HIV acquisition through condomless anal sex (1A) • PrEP with on demand or daily oral TD-FTC should be offered to HIV-negative MSM whose regular partners are newly diagnosed with HIV infection, until the partner's serum viral load reaches undetectable levels (1C) • TD alone should not currently be offered as PrEP to MSM (2C)
PrEP adverse effects. Adverse effects are an uncommon cause of discontinuing PrEP. 365 Gastrointestinal effects were reported in <10% of those receiving TDF-FTC as PrEP in iPrEx were mild and resolved within one month of initiating therapy. 360 Proximal renal tubular dysfunction and measurable loss in bone mineral density have been reported with therapeutic tenofovir (TDF) use. A 1% reduction in bone mineral density was observed when TDF was used as PrEP but has not been associated with increased fracture rate and no increase in renal complications was reported. 366 Viral resistance to either TDF or emtricitabine was rare and almost all cases were thought to be infected at or immediately after enrolment in the study. 360, 361 A modelling study of the UK epidemic suggested resistance would have a negligible impact on PrEP efficacy at a population level. 367 Baseline HIV testing using fourth generation serological testing, supported by a POCT if indicated, should always be undertaken on commencing PrEP, but a history of condomless sex within the HIV window period was not an exclusion criterion in the PROUD study. Starting PrEP should be avoided in men with current symptoms suggestive of HIV seroconversion until infection can be reliably excluded. There was no evidence of risk compensation with the use of PrEP in iPrEx, but this was a placebocontrolled study. 368 In the PROUD study, after adjustment for the number of STI screens, there was no difference in the rate of bacterial STI between the immediate and deferred groups and the rate of rectal infections was the same (RR 1.00) in both groups. However, a greater proportion of the immediate group reported receptive anal sex without a condom with ten or more partners at one year compared to the deferred group (21% versus 12%, p=0.03). 361 In the open label phase of the IPERGAY study there was a decrease in overall reported condom use over time (P=0.0003) 369 and a large observational cohort of MSM on PrEP reported that condom use declined in 41% of those on PREP. 370 There is therefore some evidence of risk compensation among MSM taking PrEP; however, longer term real-world data are lacking. Repeat HIV testing and tests for other STIs should be offered every three months. 235, 364 Serum creatinine and estimated glomerular filtration rate should be checked every 3-6 months and hepatitis C serology at least once a year. Routine urinalysis for proteinuria with urinary protein:creatinine ratio and albumin:creatinine ratio if there is more than a trace of protein is recommended by some authorities. Provision of behavioural interventions alongside routine monitoring may be indicated in reducing the frequency and/or duration of PrEP use but there is currently very little evidence to support recommendations in this area. Awareness and availability of PrEP. Awareness of and willingness to use PrEP is higher in MSM than in other groups, most studies having been conducted in the US. 371 Community-based surveys in London 372 and Scotland 373 have assessed awareness and willingness to use PrEP among UK MSM. In both studies around half of men questioned would consider PrEP use and reporting condomless anal sex was associated with a higher likelihood of considering PrEP. An online study of MSM from Scotland, Wales and Northern Ireland who reported condomless anal sex with !2 men in the last year showed 34.5% of participants were aware of PrEP but 58.5% reported that they would be willing to use PrEP if it were available to them. 374 A qualitative study of focus groups including MSM revealed concerns about adherence, condom non-use and other STIs. 375 Use of PrEP following inclusion in RCTs is higher in older and more educated men, 365 suggesting that additional information and publicity about PrEP is required to ensure equity of access. Cost-effectiveness of PrEP is highly dependent upon HIV incidence rates and the price of drug. [376] [377] [378] Targeting MSM in serodiscordant relationships (in the absence of treatment) is most cost effective but has negligible effect on HIV incidence and less relevant as early treatment becomes the norm.
376,379 UK costeffectiveness studies give a wide range of possible outcomes in sensitivity analyses showing that PrEP costeffectiveness in MSM is highly dependent upon uptake, duration of use, drug costs, real-life effectiveness and changes in HIV test uptake and condom use resulting from PrEP availability. Identification of subgroups of MSM with the highest HIV incidence, managing the duration of PrEP use and the use of event-based PrEP and obtaining antiretrovirals at a reduced price on the patent expiry of Truvada (Gilead Sciences, Foster City, California, US) in 2018 will be critical to ensuring cost-effective implementation. 380, 381 PrEP access in NHS England is planned through a large-scale clinical trial (IMPACT) enrolling 10,000 participants over three years. 382 The European Medicines Agency recommended that Truvada was granted a marketing authorisation in Europe for PrEP in July 2016. In Scotland, a marketing license for PrEP was granted by the Scottish Medicines Consortium in April 2017, allowing PrEP to be made available through NHS clinics from July 2017. Where PrEP is indicated but not accessible through the NHS in the UK, MSM have accessed medication through private medical clinics or online. Purchase of PrEP online is increasingly routine. 383, 384 Guidance for individuals who wish to pursue this route is available and the GMC has provided advice for UK clinicians wishing to support monitoring (including therapeutic blood monitoring) for those using this route. Generic versions of Truvada can be legally imported to the UK for personal use. 383 Guidance for patients on importing PrEP for personal use and on MRHA regulations is available online. 385 Clinicians should clarify local arrangements for provision of advice and monitoring for non-NHS supplied medications. MSM obtaining PrEP either through NHS provision or personal import should be provided with detailed guidance on the on-demand use of PrEP where appropriate 364 and recommended tests including baseline fourth generation HIV test and serum creatinine.
• MSM at risk of HIV infection should be made aware of the availability of PrEP through all services providing sexual health care (1C) • If PrEP is not available to men at risk who are willing and able to pay for it, they should be directed to guidance on reputable sources of medication (1D) • PrEP provision should include condom provision and behavioural support (1D) Antiretroviral post-exposure prophylaxis following sexual exposure (PEPSE)
A BASHH/BHIVA guideline on PEPSE was updated in 2015. 386 PEPSE provision is not recommended in cases where the index individual is HIV-positive with a viral load of <200 copies/ml, regardless of the type of sexual exposure. Convenience samples of HIV-negative MSM found that 34% of MSM in Spain and 36% in the USA were aware of PEPSE availability; having a higher number of sex partners was significantly associated (OR 5.1, p=0.02) with higher rates of awareness. 387, 388 Awareness was higher (52-66%) in MSM living with HIV. 389, 390 Men who accessed PEPSE in Los Angeles were found to have greater odds of having had gonorrhoea or to have used methamphetamine or inhaled nitrites in the previous year than other men who were 'high risk', but there was no difference by race or ethnicity. 391 Analysis of an Australian database of PEP prescribing found that repeat presentation for PEPSE occurred in 17.5% of users and that 1.2% of individuals were HIV-positive at baseline. 392 Higher lifetime and recent sexual risk behaviour was associated with lower adherence to PEPSE in a small study of high risk, methamphetamine-using MSM. 393 An increased HIV incidence of 6.4 per 100 person-years among MSM prescribed PEPSE versus 1.6 in a control group was found in an Amsterdam cohort of MSM 394 and was higher in PEPSE users than other MSM in an Australian data linkage study. 395 A UK study comparing 8801 MSM receiving PEPSE between 2011 and 2013 with 141, 151 who did not, found an adjusted HR of subsequently receiving a positive HIV diagnosis in the same service of 1.19 (1.04-1.37) in those who had received PEPSE, 396 suggesting that PEPSE use is a marker of elevated risk. PEP prescribing outside the parameters defined in UK guidelines is relatively common and is unrelated to prescriber's grade, setting or experience. 397 Emergency departments need education, training 398 and protocols to increase health care provider knowledge and use of PEP. 399 
• PEPSE should be provided through sexual health and out-of-hours services and availability publicised to MSM (1C) • Education of emergency department staff and local protocols are required to ensure appropriate advice, baseline HIV testing and follow-up for MSM who present requesting PEPSE (1C) • MSM who present for PEPSE constitute a high-risk population and should be offered additional prevention interventions including frequent HIV and STI testing and PrEP (1B)
Sexual health of HIV-positive MSM
The sexual health needs of MSM living with HIV should be addressed at diagnosis and as part of routine holistic HIV care and monitoring. 400 Guidance on sexual and reproductive health of people living with HIV (2008) 401 (currently undergoing revision), the management of STIs in people living with HIV (2006) 402 and on Safer Sex advice (2012) 45 are directly applicable to MSM living with HIV, but do not incorporate recent significant developments relating to the reduction in risk of sexual transmission. Following a diagnosis of HIV, highly significant reductions in partner numbers were observed in the first 12 months in a cohort of 193 MSM. 403 There is evidence that among MSM the number of episodes of UAI with partners of unknown status and the age-adjusted number of sexual partners do not increase up to five years after diagnosis. 404 A UK study using phylogenetic analysis and clinical data found that HIV transmission was strongly associated with younger age, recently-acquired HIV infection, being antiretroviral therapy (ART) naive or having concomitant STI. The majority of new infections appeared to be acquired from men who had not yet been diagnosed with HIV. 405 Mathematical modelling suggests that the proportion of new infections attributable to transmission from undiagnosed men is 82%. 184 The contribution of MSM on effective treatment to onward HIV transmission is likely to be small. However, the population rate of acute bacterial STI is up to four times higher in HIV-infected compared to HIV-uninfected or undiagnosed men and this ratio appears to have increased over recent years. . 407 Only 2% of couples in the trial were MSM. A comparable reduction in transmission risk attributable to ART was reported in a small longitudinal clinic-based study of 859 MSM in whom a likely transmitter was identified by phylogenetic analysis in 41 cases. 405 Interim findings from the PARTNER study updated in July 2016 98, 408 included 22,000 occasions of anal sex in 340 gay MSM couples. The upper 95% confidence limit for the risk of transmission per year through anal sex with a partner with undetectable serum HIV viral load was 0.89% (2.7% in the subgroup reporting receptive anal sex with ejaculation) due to the low number of person-years accumulated. However, no phylogenetically linked transmissions occurred despite 16% of MSM acquiring other STIs during follow-up and the lower 95%CI for the risk of transmission was zero. The investigators' best estimate for the risk of transmission was zero. Thirty-four per cent of men reported condomless sex with other partners, underlining the potential risk of both other STIs and of HIV acquisition from non-primary partners. A systematic review of studies of oral HIV transmission risk in cohorts including untreated individuals reported a non-zero upper confidence limit based on limited data 409 but biological data 410 and longitudinal studies support the contention that the risk is significantly lower than that for vaginal or anal sex and may be zero in some untreated individuals. 45 There is no published estimate for an upper confidence limit for transmission risk through oral sex with undetectable HIV viral load but given that sexual behaviours in both HPTN 052 and the PARTNER study would include oral sex in both heterosexual and MSM couples, it seems that a best estimate of transmission risk for oral sex with undetectable viral load is zero. It also follows that this estimate can be made with greater confidence than for vaginal or anal sex. BHIVA Treatment Guidelines recommend that the benefits of starting treatment to reduce transmission (TasP) should be discussed with all HIV-positive patients at diagnosis and treatment initiated if the patient wishes. 411 Modelling suggests that starting ART at diagnosis is both cost effective and cost saving in MSM in the UK. 412 NHS England has published a Clinical Commissioning Policy on Treatment as Prevention. 413 STI testing for HIV-positive MSM. Of MSM newly diagnosed with HIV in England in 2013, 25% had a concurrent STI and in that year MSM with diagnosed HIV infection accounted for 40% of all new syphilis diagnoses. 13 In 2008-9, 6.7% of MSM had an incident STI in the year after diagnosis (excluding those at baseline), the rate being 18.8% in MSM aged 16-19 years. 414 Routine testing of cohorts of MSM in HIV clinics reveals high rates of asymptomatic STIs 101,415-418 and a systematic review found a point prevalence in all HIV-infected individuals of 16%. 97 Opt-out selfscreening is effective and acceptable 34 and the detected incidence of STIs in MSM was doubled when testing was supported by prompts in the electronic patient record. 419 BASHH/BHIVA/FSRH sexual health in HIV guidelines recommend at least an annual offer of STI screening 401 and the BHIVA monitoring guideline recommends 3-6-monthly syphilis testing to increase detection of asymptomatic infections, 400 consistent with BASHH guidance for all MSM. 76 Regular serological testing for syphilis can increase the detection of asymptomatic infections. 420 Cost-effectiveness analysis suggests that three-monthly syphilis testing is cost effective in HIV-infected MSM. 226 Hepatitis C infection is more common in HIV-infected MSM 421, 422 and annual antibody testing is recommended, with more frequent testing for those with specific risk factors (see 'Herpes simplex virus [HSV]' section). Bacterial STIs are common in MSM screened as part of routine HIV care 416 but PN procedures may be incomplete in HIV clinics. Having an STI at baseline is an independent predictor of incident STI in HIV-infected MSM 423 and a risk score developed from observational data on 2129PY of follow-up in a large cohort of HIV-infected MSM identified prior STI, UAI with other HIV-infected men, >10 partners and methamphetamine use as predictors of asymptomatic bacterial STI. 424 Similar predictors have been identified in other cohorts. 425 These predictors closely parallel predictors in HIV-negative MSM (see: Recall arrangements and frequency of routine STI and HIV testing, p11) but identification requires regular sexual history taking which is not always reliably performed. 426 Inclusion of sexual risk assessment and history taking in an HIV care Integrated Care Pathway can improve recording. 427 A small study of the use of prophylactic doxycycline in HIV-positive MSM with a history of two or more episodes of syphilis showed a highly significant reduction in new diagnoses of bacterial STI despite lower levels of condom use 428 but this is not routine practice in the UK. 
Sexual problems and dysfunctions in MSM
Introduction
Sexual problems and dysfunctions affecting MSM can have significant adverse effects on quality of life and have been associated with a self-reported history of sexually transmitted infections in a large cross-sectional internet survey sample. 429 It has also been argued that they can contribute to sexual risk taking. [430] [431] [432] In addition to individual interventions, suggested population interventions have included greater clarity on the criminalisation of HIV transmission and efforts to reduce HIVrelated stigma. 433 
Clinical features and aetiology
Problems including low sexual desire, erectile dysfunction (ED) and ejaculatory dysregulation have been reported in large samples of MSM across the UK, US, Australia and Europe. [429] [430] [431] [433] [434] [435] [436] Distress associated with anodyspareunia (pain with receptive anal penetration) has also been reported as having a negative impact on sexual pleasure and activity. 436 Sexual problems are associated with depression, performance anxiety, low self-confidence and poor selfimage 429, 431, 433, 437 and there are complex interactions between depression, anxiety, general wellbeing, sexual risk taking and HIV infection. 431, 432 Recreational drug use and problematic alcohol use have also been identified as risk factors for sexual dysfunction. 429, 437 MSM living with HIV report greater numbers of sexual problems and dysfunctions compared to MSM who are HIV-negative. 431, 435, 436, 438 This has been related to psychological factors 432 and to duration of ART, but no association has been found with any specific class of antiretrovirals. 439 Sexual problems such as erectile dysfunction have also been associated with using sex as an avoidant strategy to cope with daily life stress and sexual risk taking in casual encounters. 430 Both delayed ejaculation (PE) and erectile difficulties have also been associated with antidepressant SSRIs in HIV-positive MSM. 432 
Diagnosis
Men may present with symptoms of sexual dysfunction as the primary concern. However, questions relating to sexual dysfunction should be part of the routine assessment of men reporting high-risk sexual behaviour. Particular attention should be paid to men living with HIV and those reporting problematic alcohol or recreational drug use. Identifying whether the problem is primary or secondary is helpful in directing treatment.
Recommendation
• Assessment of sexual risk behaviour in MSM should include routine inquiry into sexual dysfunction (2C)
Management
To date, evidence-based reviews and treatment guidelines for psychological interventions with male sexual difficulties have been based on heterosexual men. It has been argued that the models used to conceptualise and treat sexual problems such as ED or premature ejaculation (PE) are based on the heterosexual experience, with little acknowledgement of how it could be different for MSM. 440 Such issues are likely to apply to the assessment of suitability for, but not the prescribing of, pharmaceutical therapies. There is also a general lack of evidence to guide a more holistic sense of sexual wellbeing in MSM. An analysis of nearly 13,000 UK responses from the 2010 European
Men-who-have-sex-with-men Internet Survey to a general question on what constitutes the 'best sex' 441 found that the most commonly identified theme was a desire for sex within committed relationships, followed by a desire for sex that is emotionally or psychologically connected.
A recent systematic review 442 concluded that psychological therapies improved sexual functioning but it was recognised that the methodological quality of many of the studies was limited. International Society for Sexual Medicine evidence-based guidelines for psychological interventions in men who have ED and PE concluded that the psychological literature has made an important contribution to the description, aetiology and diagnosis of these difficulties but there is a lack of large, randomised and controlled studies demonstrating the efficacy of such interventions. 443 Interventions for ED included psychodynamic interpretations of anxiety, systematic desensitisation, sensate focus, couples therapy, behavioural experiments, psychosexual education, communication skills training and masturbation exercises. Overall, it is not clear which of these interventions in combination or alone has the greatest efficacy but the evidence clearly indicates that these interventions help men to improve their relationship and sexual life. 443 For PE, psychological interventions range from psychodynamic to systemic, behavioural and cognitive approaches. Besides teaching self-control techniques to delay ejaculation, psychological interventions aim to reduce performance anxiety, improve communication with sexual partners and resolve issues that precipitate and maintain the sexual problem. Psychological interventions for PE are generally effective but the evidence base for such interventions is not considered to be as clear or reliable as the findings from the research on ED. 444 Combining pharmacological and psychological treatments can be especially useful in men with acquired PE where there is a clear psychosocial precipitant or lifelong cases where the individual or couple's responses to PE are likely to interfere in the medical treatment and ultimate success of therapy. 445 NICE has recently issued guidance on the use of dapoxetine in the first-line treatment of PE. 446 For men with PE and comorbid ED, combination therapy may also be helpful to manage the psychosocial aspects of these sexual dysfunctions. 444 The existing guidelines for treating men who have sexual dysfunctions such as ED and PE, 443, 444, 447 including men who are HIV-positive, 401 are applicable to working with MSM. However, none of these guidelines provide specific guidance in working with MSM, regardless of HIV status. 
Recommendations
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Assessment of severity of dehydration
Guidance on collecting a faecal specimen for microbiological examination Advice on preventing spread of infection 285 • Hands should be washed thoroughly with (preferably liquid) soap in warm running water and dried after going to the toilet and before preparing or serving food or eating meals.
• Towels and flannels should not be shared.
• A flush toilet should be used if possible. If a commode or bedpan must be used, it should be handled with gloves, the contents disposed of into the toilet and the container then washed with hot water and detergent and allowed to dry.
• Soiled clothing and bed linen should be washed separately from other clothes and at the highest temperature they will tolerate (for example 60 C or higher for linen), after removal of excess faecal matter into the toilet. Soaking in disinfectant is not necessary. The washing machine should not be more than half full to allow for adequate washing and rinsing.
• Toilet seats, flush handles, basin taps, surfaces and toilet door handles should be cleaned at least once daily with hot water and detergent. A disinfectant (if available) and a disposable cloth (or one dedicated for toilet use) should be used to clean toilets.
• They should not go to work or other institutional settings until at least 48 h after diarrhoea has stopped. Public health authorities will advise if a pathogen is isolated from the person's stool sample: longer periods of exclusion are required in some circumstances.
• They should avoid entering swimming pools for two weeks after the last episode of diarrhoea.
